Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting ...
A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative ...
Department of Health and Aging Australia. The Review of the AR-DRG Classification System Development Process: Brisbane, QLD, Australia: PricewaterhouseCoopers; 2009. 2. Klein-Hitpass U, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results